Remdesivir, marketed as Veklury, remains an approved treatment option for COVID-19, with evolving indications since its initial emergency use authorization in 2022. The Food and Drug Administration (FDA) granted full approval for its use in hospitalized adults and children aged 12 years and older in October 2020, and later expanded that approval to include certain outpatient and pediatric populations.
Currently, Veklury is prescribed for both hospitalized and non-hospitalized patients with mild-to-moderate COVID-19 who are at high risk for progression to severe disease, including hospitalization or death. The medication is indicated for children weighing at least 3 pounds, as well as adults.
Recent research, published in January 2025, has begun to explore the impact of remdesivir on patients after acute COVID-19 infection. A study conducted by researchers at Semmelweis University in Budapest, Hungary, investigated whether remdesivir treatment during hospitalization for COVID-19 influenced the development of post-COVID condition (PCC), focusing on patient-reported outcomes and functional assessments. The study, led by Dorottya Fésü, assessed patients who had previously required oxygen therapy during their initial COVID-19 hospitalization.
The FDA continues to authorize remdesivir for treatment of hospitalized adult and pediatric patients with confirmed or suspected COVID-19. However, the specific patient populations and treatment protocols are subject to ongoing evaluation and updates based on emerging clinical data and public health needs.
